Prelog, Martina and Jeske, Samuel D. and Asam, Claudia and Fuchs, Andre and Wieser, Andreas and Gall, Christine and Wytopil, Monika and Mueller-Schmucker, Sandra M. and Beileke, Stephanie and Goekkaya, Mehmet and Kling, Elisabeth and Geldmacher, Christof and Rubio-Acero, Raquel and Plank, Michael and Christa, Catharina and Willmann, Annika and Vu, Martin and Einhauser, Sebastian and Weps, Manuela and Lampl, Benedikt M. J. and Almanzar, Giovanni and Kousha, Kimia and Schwaegerl, Valeria and Liebl, Bernhard and Weber, Beatrix and Drescher, Johannes and Scheidt, Joerg and Gefeller, Olaf and Messmann, Helmut and Protzer, Ulrike and Liese, Johannes and Hoelscher, Michael and Wagner, Ralf and Ueberla, Klaus and Steininger, Philipp (2024) Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults. JOURNAL OF CLINICAL VIROLOGY, 170: 105622. ISSN 1386-6532, 1873-5967
Full text not available from this repository. (Request a copy)Abstract
Background: SARS-CoV-2 variants of concern (VOC) may result in breakthrough infections (BTIs) in vaccinated individuals. The aim of this study was to investigate the effects of full primary (two-dose) COVID-19 vaccination with wild-type-based SARS-CoV-2 vaccines on symptoms and immunogenicity of SARS-CoV-2 VOC BTIs. Methods: In a longitudinal multicenter controlled cohort study in Bavaria, Germany, COVID-19 vaccinated and unvaccinated non-hospitalized individuals were prospectively enrolled within 14 days of a PCR-confirmed SARS-CoV-2 infection. Individuals were visited weekly up to 4 times, performing a structured record of medical data and viral load assessment. SARS-CoV-2-specific antibody response was characterized by anti-spike -(S)-and anti-nucleocapsid-(N)-antibody concentrations, anti-S-IgG avidity and neutralization capacity. Results: A total of 300 individuals (212 BTIs, 88 non-BTIs) were included with VOC Alpha or Delta SARS-CoV-2 infections. Full primary COVID-19 vaccination provided a significant effectiveness against five symptoms (relative risk reduction): fever (33 %), cough (21 %), dysgeusia (22 %), dizziness (52 %) and nausea/vomiting (48 %). Full primary vaccinated individuals showed significantly higher 50 % inhibitory concentration (IC50) values against the infecting VOC compared to unvaccinated individuals at week 1 (269 vs. 56, respectively), and weeks 5-7 (1,917 vs. 932, respectively) with significantly higher relative anti-S-IgG avidity (78% vs. 27 % at week 4, respectively). Conclusions: Full primary COVID-19 vaccination reduced symptom frequencies in non-hospitalized individuals with BTIs and elicited a more rapid and longer lasting neutralization capacity against the infecting VOC compared to unvaccinated individuals. These results support the recommendation to offer at least full primary vaccination to all adults to reduce disease severity caused by immune escape-variants.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; SARS-CoV-2; Breakthrough infection; Vaccine effectiveness; COVID-19 symptoms; Antibodies; Viral load |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene Medicine > Institut für Epidemiologie und Präventivmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 07 May 2024 13:48 |
| Last Modified: | 11 Mar 2025 06:26 |
| URI: | https://pred.uni-regensburg.de/id/eprint/62442 |
Actions (login required)
 |
View Item |
